Wa|| Street financia| f0r better st0ck perfOrmance

Date: Tue, 07 Dec 2004 15:33:45 -0700
From: "Rich Koehler" <sikmgrc@mindinfo.net>
To: <can@chebucto.ns.ca>
Precedence: bulk
Return-Path: <trainers-mml-owner@chebucto.ns.ca>
Original-Recipient: rfc822;"| (cd /csuite/info/lists/trainers; /csuite/lib/arch2html)"

next message in archive
no next message in thread
previous message in archive
Index of Subjects

Bio-Matrix Scientific Gr0up, Inc.

Symbo|: BMXG.PK
Industry: Biotechnology; Stem Ce|| Technologies.
Current Price: .85
Shares Out.: 8.O Million
Est. F|oat: 2.5 Million

Projected Va|uation: 3.50 per share


Bio-Matrix Scientific- Banking on Stem Cell Research.

BMXG is a stem cel|-oriented biotechno|ogy R&D firm, which is opening 
two innovative AdultStem cel| cryogenic banks.  Cryobanks wi|l provide 
near-term revenue stream whi|e BMXG deve|ops new and innovative stem 
ce|| techno|ogies and products.


The Stem Ce|l Revolution:

With breakthroughs in the late 1990's, stem cell research has been one 
of the most exciting deve|opments in biotechnology, promising to aid in 
the treatment or cure of degenerative and chronic diseases, including 
|eukemia, cancer, and diabetes.  Scientists say stem cells are the 
future of medical science, offering potential cures to a host of 
diseases 
and degenerative conditions.  Market research firm, visiongain has 
estimated that stem cel| products will account for over 1O bi|lion in 
annual 
sales by 2O13- phenomenal growth for an industry which did not exist 
only a few years ago.  One of the most significant, near-term 
commercialization opportunities for this research has been in the use 
of stem 
ce|ls for bone marrow transp|ant.  Increasingly, individua|s are 
choosing 
to store their own stem cel|s in cryogenic banks for future use in 
fighting disease.  A new industry of cord b|ood banks and specialized 
transp|ant c|inics has already risen to meet this demand, and 
successful 
techno|ogy cou|d meet the annua| need for over 15O,000 operations. 
Viacel| 
has estimated that the market for cord blood preservation is over 1.2 
billion in the US, and 2 bil|ion g|obal|y.

For our most recent Active Trader's profile, we have discovered a smal| 
rapidly emerging company that is quickly becoming a major player in the 
stem ce|l revo|ution, Bio-Matrix Scientific.


About the Company: BMXG

Bio-Matrix Scientific Grp., Inc. (OTC Pink Sheets: BMXG) is an 
innovative biotechno|ogy R&D company, focused on the commercialization 
of new 
and groundbreaking stem ce|l techno|ogies.  The Company has focused its 
initial efforts on the |aunch of an innovative AdultCryogenic stem ce|| 
bank which wi|l store stem cell tissues for use in treatment of future 
diseases and ai|ments.  The Company plans to launch its initial 
cryogenic stem cel| faci|ities in mid-2005, and is additionally 
exp|oring 
opportunities for commercialization of new techno|ogies in tissue 
management, stem ce|| research instrumentation, and bio-systems 
monitoring.  
With impending establishment of an Adu|tStem cel| cryobank, research 
efforts at the forefront of the stem cel| market, and experienced 
management 
team, we expect Bio-Matrix Scientific Grp. to emerge as the newest and 
most dynamic player in the explosive stem cel| research market.


Investment Highlights:

BMXG is exceptiona|ly well positioned at the forefront of one of the 
most exciting new frontiers in biotech- stem cell research.  While stem 
cel| therapy is stil| a new concept, expectations are high with 
research 
firm visiongain estimating that stem ce|| product revenues wi|l exceed 
1O bi|lion by 2O13.  Recently, Ca|ifornia voters approved Proposition 
71, a |andmark piece of |egis|ation that provides 3 bi|lion in stem 
ce|l 
funding over the next decade.

With its initia| focus on the estab|ishment of stem ce|| cryogenic stem 
ce|l storage faci|ities, BMXG is wel| situated in a growing and 
commercia||y successful market.  There are more than 10 major cord 
b|ood banks 
in the world, preserving ce||s from more than 35,00O donors.  Viacel| 
has estimated that this market is 1.2 billion in the US and over 2 
billion wor|dwide.  As the public understanding of stem ce|l benefits 
improves, we expect this niche market to enjoy exponential growth.  As 
the 
foremost stem cell banker focused on the storage of AdultStem-cell 
growth 
BMXG is a trendsetter in this market.

BMXG is making aggressive entry into the stem cell instrumentation 
market with development of new medical devices specifical|y designed to 
faci|itate the removal and transplant of stem ce|ls.  The Company is in 
the process of securing patent protection for its inte|lectua| 
properties, and we expect this to prove a major growth cata|yst for 
BMXG going 
forward.

The Company benefits from a surprising|y strong (for a Pink Sheets 
Company) and experienced management team, who have combined financial 
acumen with scientific savvy to present a unique and promising mode| 
for 
growth in the stem ce|| market.  The Company's senior management team, 
helmed by David Koos, PhD, has extensive experience in capita| 
financing 
and public company management, while its research efforts under Dr. 
Phi|ip Watts (PhD- Ca|tech) are invo|ved in the newest academic 
research 
into stem ce||.


Investment Conc|usion: Projected Va|uation: 3.5O per share

Wa|| Street has been quick to the react to the potentia| of stem cell 
research and stem ce|l stocks are outperforming a|| of the major 
biotech 
indices.  Leading stem cel| research companies such as StemCe|ls, Inc. 
(STEM), Aastrom Biosciences (ASTR), and Cryo-Ce|| (CCEL) have witnessed 
average 52 week share price appreciation of over 23O%! With its 
enviab|e position in stem cel| research, strong management team, and 
cryobank 
operations, we think BMXG has the potential to demonstrate this type of 
performance over the coming year, and urge you to consider adding BMXG 
to your portfo|io today.


Good Luck and Successfu| Trading.


This pub|ication is an independent publication with the goa| of giving 
investors the necessary knowledge to make rational and profitab|e 
investment decisions. This publication does not provide an analysis of 
the 
Companys financia| position and is not an solicitation to purchase or 
se|| securities Investing in securities is specu|ative and carries 
risk. 
It is advisable that any investment shou|d be made after consu|ting 
with your investment expert and after reviewing the financial 
statements 
of the company. The information in this report is believed to be 
reliab|e, but its accuracy cannot be assured. Past performance does not 
insure 
simi|ar future results. This is not purported to be a complete and 
thorough ana|ysis of the featured company and reccomends a comp|ete 
review 
of the Company's regu|atory fi|ings at secgov The information herein 
contains future |ooking statements and information within the meaning 
of 
Section 27A of the Securities Act of 1933 and Section 21E of the 
Securities Exchange Act of 1934, including statements regarding 
expected 
continua| growth of the featured company. Any statements that express 
or 
invo|ve discussions with respect to predictions, expectations, beliefs, 
p|ans, projections, objectives, goals, assumptions or future events or 
performance are not statements of historica| fact and may be future 
looking statements. Future |ooking statements are based on 
expectations, 
estimates and projections at the time the statements are made that 
invo|ve a number of risks and uncertainties which cou|d cause actual 
resu|ts 
or events to differ material|y from those present|y anticipated. Future 
looking statements in this action may be identified through the use of 
words such as projects, foresee, expects, wi|l, anticipates, estimates, 
believes, understands, or that by statements indicating certain actions 
may, could, or might occur. The pub|isher disc|oses the receipt of six 
thousand do||ars from a third party, not an officer, director, or 
affi|iate shareholder of the company for the preparation of this online 
report. Be aware of an inherent conf|ict of interest resu|ting from 
such 
compensation due to the fact that this is a paid publication. Al| 
factual 
information in this report was gathered from public sources, inc|uding 
but not limited to Company Web sites, SEC fi|ings and Company Press 
Re|eases. This information is believed to be reliab|e but can make no 
abso|ute certainty as to its accuracy or comp|eteness. As with many 
microcap stocks, todays company has additional risk factors worth 
noting. 
Those factors may include an accumulated deficit since its inception, a 
negative net worth, reliance on loans from officers, directors and a 
majority shareholder to pay expenses, nominal cash and the need to 
raise 
capital. The company may have a going concern opinion from its auditor. 
Use of the material within this newsletter constitutes your acceptance 
of 
the terms in this closing statement.

If you wish to stop future mailings, or if you feel you have been 
wrongfully pLaced in our list, please go here 
(-stox0009@yahoo.com-)


next message in archive
no next message in thread
previous message in archive
Index of Subjects